title: Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes.
authors.forename: J-P
authors.initials: JP
authors.lastname: Courrèges
authors.forename: T
authors.initials: T
authors.lastname: Vilsbøll
authors.forename: M
authors.initials: M
authors.lastname: Zdravkovic
authors.forename: T
authors.initials: T
authors.lastname: Le-Thi
authors.forename: T
authors.initials: T
authors.lastname: Krarup
authors.forename: O
authors.initials: O
authors.lastname: Schmitz
authors.forename: R
authors.initials: R
authors.lastname: Verhoeven
authors.forename: I
authors.initials: I
authors.lastname: Bugáñová
authors.forename: S
authors.initials: S
authors.lastname: Madsbad
mesh_terms: D015415:Biomarkers; D001786:Blood Glucose / Q000187:drug effects; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D003925:Diabetic Angiopathies / Q000517:prevention & control*; D004334:Drug Administration Schedule; D052216:Glucagon-Like Peptide 1 / Q000008:administration & dosage / Q000031:analogs & derivatives*; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D000069450:Liraglutide; D012307:Risk Factors
chemical_list: D015415:Biomarkers; D001786:Blood Glucose; D007004:Hypoglycemic Agents; D000069450:Liraglutide; D052216:Glucagon-Like Peptide 1